Clinical Research Directory

Inclusion Criteria: * • A confirmed diagnosis of idiopathic facial (Bell's) palsy by a certified neurologist or Physician is required (Heckmann, Urban, Pitz, Guntinas-Lichius, \& Gágyor, 2019). * Both male and female patients, aged between 18 and 80 years (Holland \& Bernstein, 2014). * Symptom onset within the range of 72 hours to 7 days (Petruzzelli \& Hirsch, 1991). * A baseline House-Brackmann score of 2 to 4 is necessary (Bylund et al., 2021). * Availability for the entire trial duration and all subsequent follow-up visits. * Absence of any prior treatments (e.g., corticosteroids) for the current Bell's palsy episode. Exclusion Criteria: * • Alternate diagnoses that can explain Bell's palsy (e.g., Lyme disease, Ramsay Hunt syndrome) (Crouch, Hohman, Moody, \& Andaloro, 2023). * History of recurrent Bell's palsy episodes. * Presence of severe medical conditions such as uncontrolled diabetes or autoimmune disorders. * Pregnancy or lactation. Use of concurrent medications that could interfere with facial nerve function. * Exposure to LLLT in the past 3 months. * Active skin infections or lesions in the targeted treatment area. * Conditions or medications that induce photosensitivity. * Cognitive impairments that may interfere with comprehension or feedback about the trial. * Participation in another trial in the past month. * Traumatic, inflammatory, or infectious conditions including trauma, nerve root issues, metabolic/spinal pathologies, previous spinal surgeries, or postpartum pain due to pregnancy (Singh \& Deshmukh, 2022)